Pharmaceuticals
with passion

Corporate

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.

Read more
Corporate

Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced today that it has signed a letter of intent to acquire the Jyseleca® business from Galapagos (Euronext & NASDAQ: GLPG), a global biotechnology company headquartered in Belgium, developing transformational medicines in immunology and oncology.

Read more

Therapeutic areas

Gastroenterology

Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).

Vascular

Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.

Metabolic

In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.

Nutraceuticals & Medical foods

With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.

Covid-19

Responsibility

During COVID-19 emergency, we strived to solidify and maintain our relationships with stakeholders by supporting them through numerous initiatives across the world.
×

You’re entering Alfasigma global website

I agree